Updated from 6:57 a.m. EST
NEW YORK (
expects 2010 earnings of $4.65 to $4.85 a share, guidance that brackets the estimate of analysts of $4.74 a share.
Lilly said its forecast excludes the potential impact of health care reform in the U.S.
Lilly said it expects volume-driven revenue growth in the high-single digits, driven primarily by products Alimta, Cymbalta, Humalog, Cialis, Effient and the exenatide franchise.
The drugmaker said it plans to launch two new medicines a year starting in 2013. Lilly said it currently has more than 60 molecules in clinical development, including 25 in mid- and late-stage development.
Lilly anticipates gross margin as a percent of revenue will be flat to lower in 2010. Excluding the effect of foreign exchange rates on international inventories sold, the company said it expects gross margin as a percent of revenue to increase.
Lilly said "cash flows are expected to be sufficient" to fund capital expenses of about $1 billion, "anticipated business development activity and the company's dividend."
The company also said it anticipates annual revenue during the major patent expiry years of 2012 to 2014 of at least $20 billion, and gross margins as a percent of revenue could be between 75% and 80%.
The company, in a press release Thursday, also confirmed its 2009 earnings outlook of $4.30 to $4.40 a share on an adjusted basis.
-- Reported by Joseph Woelfel in New York.
Follow TheStreet.com on
and become a fan on
Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.